# OnCo record paper-create-x-adjuvant-capecitabine-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-create-x-adjuvant-capecitabine-nejm-2017" ;
  schema:name "Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy"@en ;
  schema:description "The Japanese and Korean trial of 910 women whose tumours had survived pre-surgery chemotherapy, in which six months of capecitabine tablets cut deaths by 41 percent, and by 48 percent in the triple-negative group; the first treatment ever shown to help after residual disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1612645>, <https://pubmed.ncbi.nlm.nih.gov/28564564/>, <https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001028> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1612645> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Masuda N, Lee SJ, Ohtani S, et al." ;
  onco:related <https://onco.cc/key-papers/paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008/>, <https://onco.cc/key-papers/paper-masuda-n-engl-j-med/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/> ;
  onco:journals <https://onco.cc/journals/nejm/> .